SPY334.89+2.52 0.76%
DIA277.50+3.08 1.12%
IXIC11,167.51+82.26 0.74%

AtriCure Announces Successful Completion of Patient Enrollment of aMAZE Clinical Trial and FDA Approval of Continued Access Protocol

AtriCure, Inc. (NASDAQ:ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced the successful completion of patient enrollment in the

Benzinga · 01/07/2020 13:11

AtriCure, Inc. (NASDAQ:ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced the successful completion of patient enrollment in the aMAZE™ clinical trial. In addition, the company announced that it has received approval from the Food and Drug Administration (FDA) for the continuation of the trial under a Continued Access Protocol (CAP) with an additional patient enrollment of up to 85 patients and the opportunity to further expand to 250 patients while the pre-market application is under review.